We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





University of Oxford Develops Rapid Testing Technology for Coronavirus; Starts Clinical Trial of Potential Drug Treatments

By LabMedica International staff writers
Posted on 31 Mar 2020
Scientists from the University of Oxford’s (Oxford, UK) Engineering Science Department and the Oxford Suzhou Centre for Advanced Research (OSCAR) have developed a rapid testing technology for the novel corona virus SARS-CoV-2 (COVID-19). More...
The new test is based on a technique which is capable of giving results in just half an hour as compared to 1.5 to 2 hours for previous viral RNA tests and does not need a complicated instrument.

The technology is also very sensitive which means that patients in the early stages of infection can be identified sooner, potentially helping to reduce the spread of the coronavirus SARS-CoV-2 (COVID-19). The technology only requires a simple heat-block which maintains a constant temperature for RNA reverse transcription and DNA amplification, and the results can be read by the naked eye, making it potentially useful in rural area or community healthcare centers.

The technology has been validated with real clinical samples at Shenzhen Luohou People’s Hospital in China. Shenzhen Luohu People’s Hospital has applied the rapid detection kits on 16 clinic samples, including eight positives and eight negatives, which have been confirmed by conventional RT-PCR methods and other clinical evidence. The test results using the rapid detection kits were all successful and the Oxford scientists are now working to develop an integrated device so that the test can be used at clinics, airports, or even for home use.

“The beauty of this new test lies in the design of the viral detection that can specifically recognize SARS-CoV-2 (COVID-19) RNA and RNA fragments. The test has built-in checks to prevent false positives or negatives and the results have been highly accurate,” said Prof. Wei Huang who led the team of researchers.

Meanwhile, researchers from the University of Oxford have launched a new clinical trial to test the effects of potential drug treatments for patients admitted to hospital with COVID-19 and the first patients have been recruited. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial will provide doctors and the health service with information they need to determine which treatments should be used. The treatments initially included in the study have been recommended by an expert panel that advises the Chief Medical Officer in England. These are Lopinavir-Ritonavir, normally used to treat HIV, and the steroid dexamethasone, which is used in a wide range of conditions to reduce inflammation. The safety and side effects of both drugs are well known. In the future, the RECOVERY trial will be expanded to assess the impact of other potential treatments as they become available. Patients who have tested positive for COVID-19 and joining the trial will be allocated at random by computer to receive one of the two drugs being studied or no additional medication. This will enable researchers to see whether any of the possible new treatments are more or less effective than those currently used for patients with COVID-19.

“There is an urgent need for reliable evidence on the best care for patients with COVID-19. Providing possible new treatments through a well-designed clinical trial is the best way to get that evidence,” said Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford, and Chief Investigator for the trial. “Adults admitted to hospital with COVID-19 should be offered the opportunity to participate in this trial and contribute to improving care for everyone. All patients will receive the standard full medical care, regardless of which treatment group they are placed in.”

Additionally, a team of researchers from the Oxford Vaccine Group and Oxford's Jenner Institute who have been working on designing a vaccine since January this year have identified a vaccine candidate and are working towards the first clinical testing phase. A chimpanzee adenovirus vaccine vector (ChAdOx1), developed at Oxford’s Jenner Institute, was chosen as the most suitable vaccine technology for a SARS-CoV-2 vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual. This also makes it safer to give to children, the elderly and anyone with a pre-existing condition such as diabetes. Chimpanzee adenoviral vectors are a very well-studied vaccine type, having been used safely in thousands of subjects, from one week to 90 years of age, in vaccines targeting over 10 different diseases.

Related Links:
University of Oxford


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Portable Electronic Pipette
Mini 96
New
Capillary Blood Collection Tube
IMPROMINI M3
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.